| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Actual costs of cancer drugs in 15 European countries
|
van Harten, Wim H
|
|
2016
|
17 |
1 |
p. 18-20
3 p.
|
artikel
|
| 2 |
ADT in prostate cancer and risk of Alzheimer's disease
|
Bagcchi, Sanjeet
|
|
2016
|
17 |
1 |
p. e12-
1 p.
|
artikel
|
| 3 |
Aggressive tobacco marketing and allegations of corruption
|
Burki, Talha Khan
|
|
2016
|
17 |
1 |
p. e12-
1 p.
|
artikel
|
| 4 |
Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia
|
Kharfan-Dabaja, Mohamed A
|
|
2016
|
17 |
1 |
p. e1-
1 p.
|
artikel
|
| 5 |
Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia – Authors' reply
|
Rambaldi, Alessandro
|
|
2016
|
17 |
1 |
p. e1-e2
nvt p.
|
artikel
|
| 6 |
A new classification for mandibular defects after oncological resection
|
Brown, James S
|
|
2016
|
17 |
1 |
p. e23-e30
nvt p.
|
artikel
|
| 7 |
A new standard of care for mantle cell lymphoma?
|
Rule, Simon
|
|
2016
|
17 |
1 |
p. 5-6
2 p.
|
artikel
|
| 8 |
Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries
|
Vranken, Marjolein J M
|
|
2016
|
17 |
1 |
p. e13-e22
nvt p.
|
artikel
|
| 9 |
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
|
Rummel, Mathias
|
|
2016
|
17 |
1 |
p. 57-66
10 p.
|
artikel
|
| 10 |
Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
|
Vogler, Sabine
|
|
2016
|
17 |
1 |
p. 39-47
9 p.
|
artikel
|
| 11 |
Cancer survivors' risk of future admission to hospital
|
Burki, Talha Khan
|
|
2016
|
17 |
1 |
p. e8-
1 p.
|
artikel
|
| 12 |
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
|
Dimopoulos, Meletios A
|
|
2016
|
17 |
1 |
p. 27-38
12 p.
|
artikel
|
| 13 |
Cervical cancer diagnosis and the US Affordable Care Act
|
Burki, Talha Khan
|
|
2016
|
17 |
1 |
p. e10-
1 p.
|
artikel
|
| 14 |
Climate change and non-communicable diseases
|
The Lancet Oncology,
|
|
2016
|
17 |
1 |
p. 1-
1 p.
|
artikel
|
| 15 |
Consume, digest, and expire: the risks of domesticated carcinogens
|
Tang, Paul Kiet
|
|
2016
|
17 |
1 |
p. 24-25
2 p.
|
artikel
|
| 16 |
Correction to Lancet Oncol 2015; 16: 303
|
|
|
2016
|
17 |
1 |
p. e6-
1 p.
|
artikel
|
| 17 |
Correction to Lancet Oncol 2016; 17: 65
|
|
|
2016
|
17 |
1 |
p. e6-
1 p.
|
artikel
|
| 18 |
Correction to Lancet Oncol 2016; 17: e8
|
|
|
2016
|
17 |
1 |
p. e6-
1 p.
|
artikel
|
| 19 |
Defining the genetics of melanoma progression
|
Burki, Talha Khan
|
|
2016
|
17 |
1 |
p. e7-
1 p.
|
artikel
|
| 20 |
Detection of DCIS and reduced invasive interval cancers
|
Evans, Andy
|
|
2016
|
17 |
1 |
p. 14-15
2 p.
|
artikel
|
| 21 |
Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study
|
Maeda, Isseki
|
|
2016
|
17 |
1 |
p. 115-122
8 p.
|
artikel
|
| 22 |
ENDEAVOR to change treatment for multiple myeloma?
|
Scheid, Christof
|
|
2016
|
17 |
1 |
p. 2-3
2 p.
|
artikel
|
| 23 |
Framing loss
|
Bianchi, Andrew
|
|
2016
|
17 |
1 |
p. 25-26
2 p.
|
artikel
|
| 24 |
Genetic mutations in paediatric cancer
|
Baker, Holly
|
|
2016
|
17 |
1 |
p. e8-
1 p.
|
artikel
|
| 25 |
Herbal medicines safety concerns in patients with cancer
|
Bagcchi, Sanjeet
|
|
2016
|
17 |
1 |
p. e10-
1 p.
|
artikel
|
| 26 |
HPV vaccines: so much learnt, so many more lessons to come
|
Brotherton, Julia M L
|
|
2016
|
17 |
1 |
p. 8-9
2 p.
|
artikel
|
| 27 |
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
|
Wang, Michael L
|
|
2016
|
17 |
1 |
p. 48-56
9 p.
|
artikel
|
| 28 |
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
|
Sankaranarayanan, Rengaswamy
|
|
2016
|
17 |
1 |
p. 67-77
11 p.
|
artikel
|
| 29 |
Importance of including patients with comorbidities in clinical trials
|
Spencer, Kristen R
|
|
2016
|
17 |
1 |
p. 17-18
2 p.
|
artikel
|
| 30 |
Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
|
Motzer, Robert J
|
|
2016
|
17 |
1 |
p. e4-e5
nvt p.
|
artikel
|
| 31 |
Internal mammary node irradiation and breast cancer survival
|
Venkatesan, Priya
|
|
2016
|
17 |
1 |
p. e9-
1 p.
|
artikel
|
| 32 |
Mature answers but new questions in indolent and mantle-cell lymphoma
|
Smith, Mitchell R
|
|
2016
|
17 |
1 |
p. 6-8
3 p.
|
artikel
|
| 33 |
Melatonin: resetting the clock of cancer progression?
|
Pinato, David J
|
|
2016
|
17 |
1 |
p. 23-24
2 p.
|
artikel
|
| 34 |
NICE guidance on pembrolizumab for advanced melanoma
|
Watson, Ian
|
|
2016
|
17 |
1 |
p. 21-22
2 p.
|
artikel
|
| 35 |
NICE restructures the Cancer Drugs Fund
|
Burki, Talha Khan
|
|
2016
|
17 |
1 |
p. e9-
1 p.
|
artikel
|
| 36 |
Nintedanib and ovarian cancer: standardise surgery in trials?
|
Kehoe, Sean
|
|
2016
|
17 |
1 |
p. 9-11
3 p.
|
artikel
|
| 37 |
Palliative sedation: more data and fewer opinions
|
Caraceni, Augusto
|
|
2016
|
17 |
1 |
p. 15-17
3 p.
|
artikel
|
| 38 |
Patient risk factors versus physician guidelines for anti-emetics
|
Balakrishnan, Vijay Shankar
|
|
2016
|
17 |
1 |
p. e7-
1 p.
|
artikel
|
| 39 |
Postmarket policy considerations for biosimilar oncology drugs
|
Renwick, Matthew J
|
|
2016
|
17 |
1 |
p. e31-e38
nvt p.
|
artikel
|
| 40 |
Price, value, and the cost of cancer drugs
|
Fojo, Tito
|
|
2016
|
17 |
1 |
p. 3-5
3 p.
|
artikel
|
| 41 |
Radiation dose and checkpoint blockade immunotherapy: unanswered questions
|
Monjazeb, Arta M
|
|
2016
|
17 |
1 |
p. e3-e4
nvt p.
|
artikel
|
| 42 |
Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study
|
Duffy, Stephen W
|
|
2016
|
17 |
1 |
p. 109-114
6 p.
|
artikel
|
| 43 |
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
|
Hironaka, Shuichi
|
|
2016
|
17 |
1 |
p. 99-108
10 p.
|
artikel
|
| 44 |
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
|
du Bois, Andreas
|
|
2016
|
17 |
1 |
p. 78-89
12 p.
|
artikel
|
| 45 |
S-1 versus taxanes for HER2-negative metastatic breast cancer
|
Martin, Miguel
|
|
2016
|
17 |
1 |
p. 11-12
2 p.
|
artikel
|
| 46 |
S-1 with leucovorin for gastric cancer: how far can it go?
|
Liu, Tsang-Wu
|
|
2016
|
17 |
1 |
p. 12-14
3 p.
|
artikel
|
| 47 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
|
Takashima, Tsutomu
|
|
2016
|
17 |
1 |
p. 90-98
9 p.
|
artikel
|
| 48 |
The role of a meal on gastrointestinal toxicity and maximum tolerated dose
|
Yu, Guo
|
|
2016
|
17 |
1 |
p. e2-e3
nvt p.
|
artikel
|
| 49 |
The war on cancer: are we winning?
|
Morgan, Jules
|
|
2016
|
17 |
1 |
p. 26-
1 p.
|
artikel
|
| 50 |
Use of antidepressants and breast cancer recurrence
|
Baker, Holly
|
|
2016
|
17 |
1 |
p. e11-
1 p.
|
artikel
|
| 51 |
Venetoclax targets BCL2 in chronic lymphocytic leukaemia
|
Brower, Vicki
|
|
2016
|
17 |
1 |
p. e11-
1 p.
|
artikel
|
Tijdschrift beschrijving